The Veterinary Pharmacovigilance and Medicines Information Centre is responsible for the monitoring of veterinary adverse drug reactions in South Africa. An overview of reports of suspected adverse drug reactions received by the centre during the period March 2002 to February 2003 is given. In total, 40 reports were received. This had declined from the previous year. Most reports involved suspected adverse reactions that occurred in dogs and cats. Most of the products implicated were Stock Remedies. The animal owner predominantly administered these products. Only 1 report was received from a veterinary pharmaceutical company. Increasing numbers of reports are being received from veterinarians.
INTRODUCTION
Veterinary medicinal products in South Africa are currently registered under 2 Acts and are administered by 2 
MATERIALS AND METHODS
The Veterinary Pharmacovigilance and Medicines Information Centre relies on spontaneous reports of suspected adverse drug reactions. Reporting is voluntary and reports may be received from veterinarians, paraveterinary professionals, pharmacists, the general public, medical practitioners and Registration Holders.
Reporters are requested to complete and submit a form, which is published in the Index of Veterinary Specialities (IVS). Reports can also be faxed or e-mailed. Upon receipt, each report is provided with a date and given a sequential number. The minimum information to be provided in each report is: an identifiable source (name and contact details of reporter), animal details (species, sex, age), suspected product (name and/or registration number) and reaction details. If some of this information does not appear on the report, the reporter is asked to submit futher details.
Reports that contain all the above-mentioned information are entered into a computerised database. Thereafter the report is presented at the next meeting of the Veterinary Pharmacovigilance Working Group. At these meetings, each report received since the previous discussion is evaluated and assigned a causality classification (Table 1) .
Reports are then forwarded to the relevant regulatory authority together with an evaluation and recommendation. The Registration Holder is also informed of any report of a suspected adverse reaction to one of their products that they have not submitted themselves.
RESULTS
The Veterinary Pharmacovigilance and Medicine Information Centre received 40 reports of suspected adverse drug reactions for the period March 2002 to February 2003. These reports are summarised and classified according to the species in which the reactions occurred (Table 2) , the registration of the implicated product under current South African legislation (Table 3) , the person that administered the implicated product to the animal (Table 4 ) and the source of the report submitted to the Veterinary Pharmacovigilance and Medicines Information Centre (Table 5) . These results are compared with those of previous years 2 . Active ingredients implicated for the current period are also summarised by causality, and classified by the species in which the reactions occurred (Tables 6-10).
DISCUSSION AND CONCLUSIONS
There was a marked decrease in the number of reports received by the Veterinary Pharmacovigilance and Medicines Information Centre during the period March 2002 to February 2003 compared to the previous year (decreased from 77 reports to 40). As in previous years, most reports concerned products used either in small animal medicine or surgery 1, 2 . Most of the reports also implicated products registered as Stock Remedies under Act 36 of 1947. These increased from 51 % to 62 % during the period under review.
During current period, animal owners administered most of the drugs, followed closely by veterinarians. The number of reports of adverse drug reactions to medicines administered by owners increased from the previous period (30 % to 50 %). It is still of concern that products to which owners have direct access, are frequently reported as causing adverse reactions. Client education to increase awareness of potential side-effects should remain a high priority.
There was a marked decrease in the 
Causality classification Criteria
Certain There is a plausible time relation between the administration and the adverse event, which cannot be explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the drug (de-challenge) is clinically plausible and the event is definitely pharmacological or phenomenological, using a satisfactory re-challenge procedure, if necessary.
Probable
There is a plausible time relationship between the administration of the drug and the adverse event, unlikely to be attributed to concurrent disease or other drugs or chemicals, and which follow a clinically reasonable response on withdrawal. A positive re-challenge is not required to meet this definition.
Possible
There is a plausible time relationship between the administration of the drug and the adverse event, but the event could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear.
Unlikely An adverse event with a temporal relationship to drug administration that would make a causal relationship improbable, and which other drugs, or chemicals or underlying disease provides plausible explanation. number of reports submitted by the pharmaceutical industry (from 38 % to 2.5 %). During the preriod under review, pharmaceutical companies were not legally bound to submit reports to the Medicines Control Council. With current amendments to Act 101/65, companies will in future be required to submit reports to the Pharmacovigilance Centre. A contributory factor to the low submission rate could have been the perception that the centre may provide negative publicity for a particular product and/or company. Such a written complaint was filed by a pharmaceutical company. It must be noted, however, that the registered names of products and company details are treated with strict confidentiality.
As mentioned above, a separate governmental body administers Act 36/47. According to the Act, companies are obliged to submit all reports of adverse drug reactions to the registrar of the Act. Thus, it is not necessary for pharmaceutical companies to submit these reports via the Pharmacovigilance Centre.
The number of reports submitted by veterinarians in the field has increased (from 36 % to 87 % during the current period). It is hoped that this trend will continue. In the interest of patient safety, I appeal to the profession to increasingly make use of the services provided by the centre.
The number of reports of suspected adverse reactions following the extralabel use of products (i.e. not registered for use in animals) has also increased, from 13 % to 19 %. The could be ascribed to the larger number of reports submitted by veterinarians rather than by pharmaceutical companies. During the period under review, the pharmaceutical industry was not legally bound to submit such reports, but the amended legislation will oblige companies to report adverse drug reactions following extra-label drug use. The aim of this amendment is to increase general awareness of drug reactions following such use of human medical products, and would would hopefully lead to enhanced safety in both humans and animals. 
